Abstract

BackgroundThe biomarker value of circulating microRNAs (miRNAs) has been extensively addressed in patients with acute coronary syndrome. However, prognostic performances of miRNAs in patients with acute heart failure (AHF) has received less attention.MethodsA test cohort of 294 patients with acute dyspnea (236 AHF and 58 non-AHF) and 44 patients with stable chronic heart failure (CHF), and an independent validation cohort of 711 AHF patients, were used. Admission levels of miR-1/-21/-23/-126/-423-5p were assessed in plasma samples.ResultsIn the test cohort, admission levels of miR-1 were lower in AHF and stable CHF patients compared to non-AHF patients (p = 0.0016). Levels of miR-126 and miR-423-5p were lower in AHF and in non-AHF patients compared to stable CHF patients (both p<0.001). Interestingly, admission levels of miR-423-5p were lower in patients who were re-admitted to the hospital in the year following the index hospitalization compared to patients who were not (p = 0.0001). Adjusted odds ratio [95% confidence interval] for one-year readmission was 0.70 [0.53–0.93] for miR-423-5p (p = 0.01). In the validation cohort, admission levels of miR-423-5p predicted 1-year mortality with an adjusted odds ratio [95% confidence interval] of 0.54 [0.36–0.82], p = 0.004. Patients within the lowest quartile of miR-423-5p were at high risk of long-term mortality (p = 0.02).ConclusionsIn AHF patients, low circulating levels of miR-423-5p at presentation are associated with a poor long-term outcome. This study supports the value of miR-423-5p as a prognostic biomarker of AHF.

Highlights

  • Acute heart failure (AHF) carries a high mortality risk and a high incidence of hospital readmission.[1]

  • Admission levels of miR-1 were lower in AHF and stable chronic heart failure (CHF) patients compared to non-AHF patients (p = 0.0016)

  • Levels of miR-126 and miR-423-5p were lower in AHF and in non-AHF patients compared to stable CHF patients

Read more

Summary

Introduction

Acute heart failure (AHF) carries a high mortality risk and a high incidence of hospital readmission.[1]. Since the discovery of miRNA presence in the bloodstream [6, 7], the potential of miRNAs to aid in disease management has been an active field of investigation. Their ability to diagnose patients with cardiovascular disease has been thoroughly addressed in small scale studies (reviewed in [8]). The biomarker value of circulating microRNAs (miRNAs) has been extensively addressed in patients with acute coronary syndrome. Prognostic performances of miRNAs in patients with acute heart failure (AHF) has received less attention

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.